For psoriatic arthritis, four small-molecule drugs were all superior to placebo and comparable with adalimumab. Upadacitinib and deucravacitinib consistently were in the top two across efficacy ...

Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the ...

Tofacitinib is a novel, small-molecule, oral selective inhibitor ... prior treatment with adalimumab; lack of response to prior anti-TNF biologic treatment; and current infection or evidence ...

In a meta-analysis of 37 studies, patients receiving infliximab were switched to adalimumab or certolizumab ... is the first of the newer small-molecule agents for the treatment of chronic ...

More than 90% of patients with inflammatory bowel disease (IBD) accepted the switch from the adalimumab reference product to adalimumab biosimilars, with favourable survival and remission outcomes ...

One of the most common current treatments for severe rheumatoid arthritis is a monoclonal antibody called adalimumab. This treatment inhibits an immune signaling molecule called tumor necrosis ...

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the TNF-alpha inhibitors infliximab (Janssen Biotech/Merck ...

While adalimumab biosimilars are just now launching in the United States, there have been options available in Europe and elsewhere for years. According to Amgen, there will be 2 tiers of pricing ...

Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared decision ...

(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), adalimumab is efficacious in conjunction with wide-excision surgery followed by secondary intention healing ...